Search the Newsreel

Should I buy Scribe Therapeutics Inc. (SCTX)

What date does Scribe Therapeutics Inc.'s (SCTX) report Earnings - Earnings Calendar & Announcement

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

Criteo (NASDAQ:CRTO) Share Price Passes Below 200-Day Moving Average - Here's What Happened

Criteo S.A. (NASDAQ:CRTO) shares recently fell below their 200-day moving average, trading as low as $18.07 before settling at $19.00. The company reported mixed financial results, beating EPS expectations but experiencing an 11.3% year-over-year revenue decline. Analyst sentiment is divided, with a consensus "Hold" …

RWWM reports 3.9% Carter's (CRI) stake held for advisory clients

RWWM, Inc. and related parties have filed an amended Schedule 13G/A, disclosing beneficial ownership of 1,443,196 shares of Carter's, Inc. (CRI), which represents 3.9% of the outstanding common stock. This stake includes shares held in client accounts, the RWWM Inc. 401(k) Profit Sharing Plan, …

Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More

The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …

CRISPR Therapeutics (CRSP): Orbis-led investors disclose 5.6% ownership stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have disclosed a combined beneficial ownership of 5,449,161 shares, or 5.6%, of CRISPR Therapeutics AG (CRSP) Common Stock as of June 30, 2026. Orbis holds the vast majority of these shares with sole voting …

Namibia Critical Metals Stock Falls 6.82%: Why TSXV:NMI Is in Focus as Lofdal Rare Earths Enters a Critical Development Phase

HC Wainwright Has Bullish Estimate for ACRV FY2030 Earnings

Vertex to acquire Crinetics after HSR clearance; closing expected early Sept

Crinetics Pharmaceuticals announced that it has received HSR clearance for its merger with Vertex. The HSR waiting period expired on August 12, 2026, and antitrust approvals have also been secured in Austria, Germany, and Australia. The merger's closing is targeted for early September 2026, …

Cutting-edge drug quells insatiable desire to eat. Experts warn it could be tied to deaths

Neurocrine's drug, Vykat XR, designed to treat the insatiable appetite associated with Prader-Willi Syndrome (PWS), is facing safety warnings following seven deaths. Patient organizations and doctors are calling for more research into the drug's safety, emphasizing that PWS patients often have multiple other health …

Carter's (CRI) Earnings Date and Reports 2026 $CRI

Strata critical medical director Reginald Love disposes of $29,273 in stock

Reginald Love, a director at Strata Critical Medical (NASDAQ:SRTA), sold 5,091 shares of the company's Class A common stock for a total of $29,273 on August 10, 2026. Following this transaction, Love still directly holds 146,481 shares. The company's stock has seen significant gains …

Carter's Earnings Rebound and Buybacks Could Be A Game Changer For Carter's (CRI)

Carter's (CRI) recently reported strong Q2 2026 results with increased sales and net income, alongside a significant share repurchase program. The company projects modest net sales growth for fiscal 2026, shifting the focus to operational execution and cost discipline for future profitability. While earnings …

Strata Critical Medical (SRTA) director Reginald Love sells 5,091 shares at $5.75

Strata Critical Medical, Inc. director Reginald Love sold 5,091 shares of Class A common stock at $5.75 per share on August 10, 2026. Following this transaction, his direct holdings in the company amount to 146,481 shares. The sale was reported in an open market …

CARTERS INC (CRI) officer has 1,124 shares withheld for taxes after vesting

Karen Marie Smith, Chief Supply Chain Officer at CARTERS INC (CRI), reported a tax-related share disposition where 1,124 shares were withheld at $39.06 per share to cover tax obligations from the vesting of restricted stock. Following this transaction on August 12, 2026, she directly …

Crinetics Pharmaceuticals (CRNX): Wellington reports 7.13M-share, 6.76% ownership

Wellington Management entities have reported beneficial ownership of 7,131,084 shares, or 6.76%, of Crinetics Pharmaceuticals (CRNX) common stock. The filing indicates shared voting power over 6,310,651 shares and shared dispositive power over all 7,131,084 shares, with economic interests belonging to advisory clients. No single …

Morgan Stanley (CRTO) discloses 9.8% Criteo ownership through Schedule 13G/A

Morgan Stanley and its subsidiary Morgan Stanley & Co. International plc have disclosed a combined beneficial ownership of Criteo S.A. through a Schedule 13G/A filing. Morgan Stanley reported a 9.8% stake, totaling 4,908,581 shares, with shared voting and dispositive power. Separately, Morgan Stanley & …

Piper Sandler Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $8

Piper Sandler has reiterated its Buy rating on Acrivon Therapeutics (ACRV.US) and maintained its price target at $8. This indicates continued confidence from the firm in the company's financial prospects and stock performance.

Sands Capital group (NASDAQ: ACRV) discloses 5.3% Acrivon ownership in 13G/A

Sands Capital Life Sciences Pulse Fund II, L.P. and its affiliated entities have disclosed a beneficial ownership of 5.3% in Acrivon Therapeutics, Inc. (NASDAQ: ACRV), totaling 2,289,271 shares. This information was reported in a Schedule 13G/A filing with the SEC, based on 42,853,362 shares …

Morgan Stanley Has Lowered Expectations for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Strata Critical Medical (SRTA) Q2 2026 Earnings Call Transcript

Scribe Therapeutics (SCTX) awards 14,725 stock options to director Bleharski

Scribe Therapeutics (SCTX) director Joshua Bleharski was granted 14,725 stock options with an exercise price of $15.00 per share, expiring on July 22, 2036. The options will vest in three equal annual installments on July 23 of 2027, 2028, and 2029, contingent on his …

Deutsche Bank Adjusts Neurocrine Biosciences PT to $165 From $190, Maintains Hold Rating

Deutsche Bank has adjusted its price target for Neurocrine Biosciences (NBIX) to $165, down from $190, while maintaining a Hold rating on the stock. This adjustment comes amidst recent news including positive Phase 4 study results for Ingrezza capsules and the initiation of a …

CRTO SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Criteo

SueWallSt has launched an investigation into Criteo (NASDAQ: CRTO) after the company drastically revised its fiscal year 2026 Contribution ex-TAC growth outlook from flat to low-single-digit growth to a 10% to 12% decline. This revision, announced on August 5, 2026, less than three months …

Strata Critical Medical, Inc. (SRTA) stock price, news, quote and history

The Top 5 Analyst Questions From E.W. Scripps’s Q2 Earnings Call

Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP

Bank of America Corp DE reduced its stake in CRISPR Therapeutics AG by 10.4% in the first quarter, selling 113,815 shares and retaining 983,072 shares valued at $46.765 million. Institutional investors collectively own 69.2% of the company, which reported a quarterly loss of $0.94 …

CRISM Therapeutics Advances Towards Patient Recruitment for Phase II Glioblastoma Trial

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has received a consensus "Moderate Buy" rating from twenty-four brokerages, with an average 12-month price target of $201.50. The company's stock opened at $156.49, has a market capitalization of $15.91 billion, and has seen significant insider selling totaling over $61 …

CRISM Therapeutics Clears Key Step to Begin Phase II Glioblastoma Trial

CRISPR Therapeutics (CRSP) Stock Looks Fairly Valued Despite Pipeline Promise

CRISPR Therapeutics (CRSP) stock has seen a significant decline over the past five years but now appears to be fairly valued. Despite promising allogeneic CAR-T programs, its Price-to-Book ratio is in line with the biotech industry average, suggesting investors acknowledge its potential without pricing …